Emergent BioSolutions Inc. is a global specialty pharmaceutical company, which offers specialized products to governments and healthcare providers. The company derives most of its revenue from one product, BioThrax, which is the only FDA-licensed vaccine for the prevention of anthrax disease. In 2015, about 56% of the company's revenue came from the sale of BioThrax with the remainder coming from the sale of their other biodefense products, biosciences products, and contract manufacturing.